FBIO - Earnings announcements

Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million  Emrosi® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27 million, driven by strong financial performance Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 13, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corp

SCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2026 financial results after the U.S. financial markets close on Wednesday, May 13, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 13, 2026 at 4:30 p.m. ET. To listen to the conference call, interested parties within the

Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately 53,000 total prescriptions were filled for Emrosi™ during FY2025 Payer access for Emrosi™ available to over 100 million U.S. commercial lives Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 25, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for t

SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2025 financial results after the U.S. financial markets close on Wednesday, March 25, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 25, 2026 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. shoul

Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the third quar

SCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its third quarter 2025 financial results after the U.S. financial markets close on Wednesday, November 12, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, November 12, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the

Second quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results an

SCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2025 financial results after the U.S. financial markets close on Tuesday, August 12, 2025. Journey Medical management will conduct a conference call and audio webcast on Tuesday, August 12, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.

Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Admin

SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2025 financial results after the U.S. financial markets close on Wednesday, May 14, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 14, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. s

FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 were $56.1 million Met All Financial Guidance for 2024 Emrosi Phase 3 Clinical Trial Results Published in JAMA Dermatology Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 26, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approve

SCOTTSDALE, Ariz., March 19, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2024 financial results after the U.S. financial markets close on Wednesday, March 26, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 26, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S.

SCOTTSDALE, Ariz., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that its management team will host a conference call to provide an update on the commercial launch plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29. The FDA approved Emrosi for the treatment of inflammatory lesions of rosacea in adults in November of 2024. Emrosi was developed i

SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the FDA has approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy's Laboratories Ltd. Claude Maraoui, Co-Founder, President, and Chief Executive Officer of Jo

New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from the $13.0 million reported in the first quarter of 2024 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for

SCOTTSDALE, Ariz., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2024 financial results after the U.S. financial markets close on Monday, August 12, 2024. Journey Medical management will conduct a conference call and audio webcast on Monday, August 12, 2024 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic)

New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7% increase from the $12.2 million reported in the first quarter of 2023 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., May 13, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical pr

SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2024 financial results after the U.S. financial markets close on Monday, May 13, 2024. Journey Medical management will conduct a conference call and audio webcast on Monday, May 13, 2024 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-3

MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader ("KOL") event highlighting expert perspectives on spinal bulbar muscular atrophy ("SBMA"), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET. The virtual event will focus on the potential of AJ201 in SBMA, including KOL perspectives on the SBMA treatment landscape, an overview of the Phase 1b/2a study evaluating AJ201 for the treatment of SBMA and outcome co

Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 Achieved $15.6 million in operating cost savings in 2023, ahead of initial guidance of $12.0 million New Drug Application for rosacea treatment candidate DFD-29 accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., March 21, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company"), a commercial-stage pharmaceutical co

SCOTTSDALE, Ariz., March 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2023 financial results after the U.S. financial markets close on Thursday, March 21, 2024. Journey Medical management will conduct a conference call and audio webcast on Thursday, March 21, 2024 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-

Company generated total net revenues of $34.5 million in the third quarter of 2023, a 101% increase from $17.2 million in the second quarter of 2023 GAAP net income increased to $16.8 million, or $0.91 per share basic and $0.80 per share diluted, for the third quarter of 2023, compared to a GAAP net loss of $10.1 million, or $0.57 per share basic and diluted for the third quarter of 2022 Received an upfront payment of $19.0 million upon entering into an exclusive license agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and other Asian nations New Drug Application for DFD-29 expected to be submitted to FDA around the end of 2023 Company to hold conference call today at 4:30 p.m

SCOTTSDALE, Ariz., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its third quarter 2023 financial results after the U.S. financial markets close on Tuesday, November 7, 2023. Journey Medical management will conduct a conference call and audio webcast on Tuesday, November 7, 2023 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domesti

The Company generated total net revenues of $17.2 million in the second quarter of 2023, a 41% increase from $12.2 million in the first quarter of 2023 Announced positive topline results from two Phase 3 clinical trials evaluating DFD-29 (minocycline hydrochloride modified release capsules, 40mg); both trials achieved the co-primary and all secondary endpoints over placebo and the current standard of care Oracea® (doxycycline, 40mg) with no significant safety issues The Company plans to submit a New Drug Application to FDA for DFD-29 in the second half of 2023 Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corp

Company to host conference call to discuss financial results and provide a corporate update on August 8, 2023 at 4:30 p.m. ET Company and Neal Bhatia, MD, Director of Clinical Dermatology, Therapeutics Clinical Research, San Diego, CA and Investigator in over 75 clinical trials including the DFD-29 Phase 3 clinical program, to discuss positive topline clinical data and disease state of rosacea on the conference call SCOTTSDALE, Ariz., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical produ

SCOTTSDALE, Ariz., July 19, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will release its second quarter 2023 financial results during the week of August 7, 2023. Journey Medical management will conduct a conference call and audio webcast. Details will be provided at a later date. About Journey Medical CorporationJourney Medical Corporation (NASDAQ:DERM) ("Journey Medical") is a commercial-stage pharmaceut

Achieved "Last Patient Out" milestone in Phase 3 clinical program evaluating DFD-29 in May 2023 Topline data are expected in June 2023 for Phase 3 clinical program evaluating DFD-29 Company to hold conference call on May 22, 2023, at 4:30 p.m. ET SCOTTSDALE, Ariz., May 22, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023. Claude Ma

SCOTTSDALE, Ariz., May 19, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2023 financial results after the U.S. financial markets close on Monday, May 22, 2023. Journey Medical management will conduct a conference call and audio webcast on Monday, May 22, 2023 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (inter

SCOTTSDALE, Ariz., May 11, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that it has postponed the release of its first fiscal quarter financial results and conference call, previously scheduled for Thursday, May 11, 2023, to provide additional time to complete the finalization of its financial statements. About Journey Medical CorporationJourney Medical Corporation (NASDAQ:DERM) ("Journey Medical") is focused on identifying, acquiring, developing and strategicall

SCOTTSDALE, Ariz., May 04, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2023 financial results after the U.S. financial markets close on Thursday, May 11, 2023. Journey Medical management will conduct a conference call and audio webcast on Thursday, May 11, 2023 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413

Generated record total revenues of $73.7 million for the full year 2022 Completed enrollment in Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea; topline data are expected in the first half of 2023 Company to hold conference call on March 29, 2023 at 4:30 p.m. ET SCOTTSDALE, Ariz., March 29, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the fourth quarter and full year en

SCOTTSDALE, Ariz., March 22, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2022 financial results after the U.S. financial markets close on Wednesday, March 29, 2023. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 29, 2023 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413

Revenue for the first nine months of 2022 increased 26% to $57.7 million versus the same period in 2021 of $45.6 million DFD-29 Phase 3 studies are 75% enrolled to date Top-line data from the Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea anticipated in the first half of 2023 Company to hold conference call on November 10, 2022 at 4:30 p.m. ET SCOTTSDALE, Ariz., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, tod

SCOTTSDALE, Ariz., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical") (NASDAQ:DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its third quarter 2022 financial results after the U.S. financial markets close on Thursday, November 10, 2022. Journey Medical management will conduct a conference call and audio webcast on November 10, 2022 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). A

Second quarter 2022 net revenue increased 20% to $18.3 million versus the same quarter of 2021 DFD-29 Phase 3 studies 45% enrolled to date; 9 additional sites underway in Europe open to enrollment Top-line data anticipated from the Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea in the first half of 2023 Company to hold conference call on August 9, 2022 at 4:30 p.m. ET SCOTTSDALE, Ariz., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment o

SCOTTSDALE, Ariz., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical") (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2022 financial results after the U.S. financial markets close on Tuesday, August 9, 2022. Journey Medical management will conduct a conference call and audio webcast on August 9, 2022 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All

Generated record revenue of $23.3 million for the first quarter of 2022 First patient dosed in Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea Company to hold conference call on May 10, 2022 at 4:30 p.m. ET SCOTTSDALE, Ariz., May 10, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2022. Claude Maraoui, Journey Medical's C

SCOTTSDALE, Ariz., May 03, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical") (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2022 financial results after the U.S. financial markets close on Tuesday, May 10, 2022. Journey Medical management will conduct a conference call and audio webcast on May 10, 2022 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers

SCOTTSDALE, Ariz., March 18, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical") (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announces it will release its year end 2021 financial results after the U.S. financial markets close on Wednesday, March 23, 2022. Journey Medical management will conduct a conference call and audio webcast on March 23, 2022 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should

Study met primary endpoint with 47.4% objective response rateSafety and tolerability profile consistent with previously reported dataPlanned BLA submission on track for later this yearConference call to be held today, Tuesday, January 25, 2022, at 8:30 AM ET WALTHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced positive topline results from its registration-enabling clinical trial evaluating the safety and efficacy of its anti-PD-L1 antibody, cosibelimab, administered as a fixed dose of 800 mg every two weeks in patients with metastatic cutaneous squamous c

95% overall response rate, 65% complete response rate and favorable safety profile in patients treated with modified cell manufacturing process Data presented at the 63rd American Society of Hematology (ASH) Annual Meeting Key opinion leader conference call on Thursday, December 16, 2021, at 2:30 p.m. EST WORCESTER, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced updated data from the ongoing Phase 1/2 clinical trial of MB-106,